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Plasma-derived sequences of human immunodeficiency virus type 1 (HIV-1) protease from 1,162 patients
(457 drug-naı¨ve patients and 705 patients receiving protease inhibitor [PI]-containing antiretroviral regimens)
led to the identification and characterization of 17 novel protease mutations potentially associated with
resistance to PIs. Fourteen mutations were positively associated with PIs and significantly correlated in pairs
and/or clusters with known PI resistance mutations, suggesting their contribution to PI resistance. In partic-
ular, E34Q, K43T, and K55R, which were associated with lopinavir treatment, correlated with mutations
associated with lopinavir resistance (E34Q with either L33F or F53L, or K43T with I54A) or clustered with
multi-PI resistance mutations (K43T with V82A and I54V or V82A, V32I, and I47V, or K55R with V82A, I54V,
and M46I). On the other hand, C95F, which was associated with treatment with saquinavir and indinavir, was
highly expressed in clusters with either L90M and I93L or V82A and G48V. K45R and K20T, which were
associated with nelfinavir treatment, were specifically associated with D30N and N88D and with L90M,
respectively. Structural analysis showed that several correlated positions were within 8 Å of each other,
confirming the role of the local environment for interactions among mutations. We also identified three
protease mutations (T12A, L63Q, and H69N) whose frequencies significantly decreased in PI-treated patients
compared with that in drug-naı¨ve patients. They never showed positive correlations with PI resistance muta-
tions; if anything, H69N showed a negative correlation with the compensatory mutations M36I and L10I. These
mutations may prevent the appearance of PI resistance mutations, thus increasing the genetic barrier to PI
resistance. Overall, our study contributes to a better definition of protease mutational patterns that regulate
PI resistance and strongly suggests that other (novel) mutations beyond those currently known to confer
resistance should be taken into account to better predict resistance to antiretroviral drugs.
Human immunodeficiency virus type 1 (HIV-1) is character-
ized by a high degree of genetic variability, mainly due to the
intrinsic inability of HIV-1 reverse transcriptase to carry out
proofreading of DNA during replication (20), and is exacer-
bated by the high rate of HIV-1 replication in vivo (109 viral
particles are produced daily), the accumulation of proviral
variants, and genetic recombination (2). Among the different
areas of the viral genome, the pol gene, which encodes en-
zymes such as reverse transcriptase and protease, is subjected
not only to natural variation pressure but also to mutations
imposed by the pharmacological treatment (6, 31).
The HIV-1 protease enzyme is responsible for the posttrans-
lational processing of the viral polyproteins encoded by gag
(p55) and gag-pol (p160), thus yielding the mature structural
core proteins (the matrix, capsid, nucleocapsid, and p6 pro-
teins) and the essential enzymes (protease, reverse transcrip-
tase, and integrase) required to produce mature infectious
particles (32).
For its crucial role in the HIV-1 life cycle, protease repre-
sents an important target for the antiretroviral therapy. To
date seven protease inhibitors (PIs; indinavir, ritonavir, sa-
quinavir, nelfinavir, amprenavir, lopinavir, and atazanavir)
have been approved by the Food and Drug Administration
(FDA) and are clinically available. Unfortunately, when anti-
retroviral therapy fails to be fully suppressive, viral variants
with reduced susceptibilities to PIs can emerge (8, 10, 21).
Resistance to PIs is mediated by the appearance of protease
amino acid substitutions (at positions either in direct contact
with the inhibitor or at distant sites) that reduce the binding
affinity between the inhibitor and the mutant protease enzyme
(6). These amino acid substitutions, defined in the literature as
major mutations, may deeply impair the protease catalytic ac-
tivity and, consequently, the replication capacity of the virus (5,
19). Restoration of the replication capacity, which allows the
viability of virus particles, is due to the presence of mutations
defined in the literature as compensatory mutations (5, 9).
Several studies have contributed to our current knowledge of
the drug-related variants of HIV-1 protease. To date, muta-
tions at 50 of 99 residues of protease have been related to one
or more experimentally tested PIs, thus attesting to the high
degree of flexibility of the protease enzyme (11, 13, 23, 29, 37);
22 of these residues are involved in resistance to the PIs used
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in clinical practice (13; Stanford HIV Drug Resistance Data-
base [http://hivdb.Stanford.edu]). Generally, single mutations
confer only a modest reduction in drug susceptibility (with
some exceptions, such as D30N, I47A, G48V, and I50L/V),
while for many PIs, particularly if they are boosted with ritona-
vir, a stepwise accumulation of several protease mutations is
required for the development of high-level drug resistance.
This requirement of multiple mutations to overcome the ac-
tivities of PIs has been referred to as a high genetic barrier to
drug resistance (7, 16, 22). Furthermore, most drug resistance
mutations in the protease confer cross-resistance to many PIs,
so this resistance should be considered class specific rather
than drug specific (10, 15, 17, 27).
Since protease is characterized by a high degree of structural
flexibility and resistance to PIs is a such complex phenomenon,
it is conceivable that the mutational pathways of HIV protease
are far more complex than is currently known and that some
mutations (and associations of mutations) have been not yet
precisely defined. For instance, previous work recently identi-
fied some positions or mutations positively associated with
treatment with PIs; however, their exact role in PI resistance
has not yet been precisely clarified (3, 23, 37). Thus, we de-
cided to focus our attention on these uncharacterized (novel)
mutations to better understand their association with specific
PIs and PI resistance-associated mutations and thus contribute
to obtaining a better definition of the protease mutational
patterns that regulate PI resistance.
The identification of new mutational clusters also suggests
that these additional mutations may interact as part of higher-
order networks and strongly suggests that other mutations
beyond those currently known to be associated with PI resis-
tance should be considered to define precise algorithms able to
predict resistance to antiretroviral drugs.
MATERIALS AND METHODS
Patients. The study included 1,162 patients enrolled either in the Italian
Cohort of Antiretroviral Naı¨ve patients (ICONA) or in different clinical
centers in central Italy; 457 patients were naı¨ve to treatment with antiretro-
viral drugs, and 705 were failing an antiretroviral regimen containing at least
one PI. Drug-naı¨ve patients underwent genotypic tests between 1 January
1997 and 31 December 2003, while PI-treated patients underwent genotypic
tests between 1 January 1998 and 31 December 2003. Overall, drug-treated
patients were exposed to an average of two PIs, 680 (96.5%) were receiving
a highly active antiretroviral therapy, and 701 (99.4%) PI-treated patients had
a well-characterized antiretroviral treatment history. In detail, 61.1% of pa-
tients had been treated with indinavir, 56.4% had been treated with nelfina-
vir, 44.3% had been treated with saquinavir, 29.8% had been treated with
ritonavir, 6.8% had been treated with lopinavir/ritonavir, 1.1% had been
treated with amprenavir, and 0.1% had been treated with tipranavir. At the
time of genotypic analysis, 47.5% of patients were receiving treatment with
nelfinavir (median time, 426 days), 29.6% were receiving treatment with
indinavir (median time, 615 days), 18.6% were receiving treatment with
ritonavir (median time, 239 days), 16% were receiving treatment with sa-
quinavir (median time, 302 days), 6% were receiving treatment with lopina-
vir/ritonavir (median time, 223 days), 1.1% were receiving treatment with
amprenavir (median time, 271 days), and 0.1% were receiving treatment with
tipranavir (median time, 14 days). Patients carrying non-B clades of HIV pol
were excluded from this analysis. Data for all patients were stored in a
specifically designed anonymous database that included mutational, demo-
graphic, immunologic, virologic, and therapeutic parameters.
HIV sequencing. HIV genotype analysis was performed with plasma samples
by means of a commercially available kit (The ViroSeq HIV-1 Genotyping
System; Applied Biosystems) (3, 26). Briefly, RNA was extracted, retrotrans-
cribed with murine leukemia virus reverse transcriptase, and amplified with the
AmpliTaq Gold polymerase enzyme by using two different sequence-specific
primers for 40 cycles. The sense and antisense orientations of the full lengths of
the pol-amplified products (containing the entire protease gene and the first 320
amino acids of the reverse transcriptase open reading frame) were sequenced by
using seven different overlapping sequence-specific primers and an automated
sequencer (ABI 3100) (3, 26). Sequences with a mixture of wild-type and mutant
residues at single positions were considered to have the mutation(s) at that
position. The isolates were subtyped by comparing their sequences to reference
sequences of known subtype (http://hivdb.Stanford.edu).
Statistical analysis. To assess the association of protease mutations with PI
treatment, we calculated their frequencies in isolates both from untreated pa-
tients and from PI-treated patients and performed chi-square tests of indepen-
dence (based on a two-by-two contingency table) to verify whether the differ-
ences in frequency between the two groups of patients were statistically
significant (P  0.05). We considered novel mutations (T12A, A22V, E34Q,
E35G, K43T, K45R, K55R, Q58E, I62V, L63Q, H69N, T74S, I85V, Q92K, and
C95F) to be those that have not yet been reported to be associated with PI
resistance by the Stanford HIV Drug Resistance Database (http://hivdb.Stan-
ford.edu) and by the International AIDS Society (13). We also included in our
analysis the novel mutations K20I and K20T, reported by the International AIDS
Society to be specifically associated with resistance to atazanavir (approved by
FDA in June 2003) and tipranavir (not yet approved by FDA), respectively, and
also recently reported in the Stanford HIV Drug Resistance Database.
To assess the association of each novel mutation with treatment with a specific
PI, we compared the rate of occurrence of each novel mutation in the subpopu-
lation that experienced treatment with a specific PI with that in the subpopula-
tion that did not experience treatment with that PI; we then performed chi-
square tests of independence to verify statistically significant differences (P 
0.05).
We used the Benjamini-Hochberg method (1, 37) to identify results that were
statistically significant in the presence of multiple-hypothesis testing. A false
discovery rate of 0.05 was used to determine statistical significance.
Mutation covariation. We calculated the binomial correlation coefficient (phi)
for all the possible pairwise combinations between novel mutations and the other
protease mutations in the set of PI-treated patients. Statistically significant pair-
wise correlations were those with a P value of 0.05. We used the Benjamini-
Hochberg method (1) to identify pairwise combinations that were significant in
the presence of multiple-hypothesis testing. A false discovery rate of 0.05 was
used to determine statistical significance.
For each pair, two positions each with a mixture of two or more mutations
were excluded from the covariation analysis, since it is impossible to discriminate
whether these mutations fall in the same viral genome.
Mutational clusters were defined as clusters of three or more mutated posi-
tions in which each position was significantly correlated with each other. Muta-
tional clusters were identified by a computational technique that evaluated all
possible clusters that can be formed from the significant correlated pairwise
combinations of mutated positions. The computational technique was performed
with the S-Plus program by implementation of hierarchical clustering algorithms.
For the box-plot analysis, we considered D30N, V32I, M46I/L, I47A, G48V,
I50L/V, I54A/L/M/S/T/V, V82A/F/S/T, I84V, N88D/S, and L90M to be major
mutations (13; Stanford HIV Drug Resistance Database [http://hivdb.Stanford
.edu]).
Structural analysis. The X-ray crystallographic coordinates with the code
1HIH.pdb deposited in the Protein Data Bank (PDB; http://www.rcsb.org/PDB/)
were used as the template for structural analysis. Deep View (version 3.7)
software was used to map amino acids onto the three-dimensional representation
of the protease enzyme and to inspect the structures for hydrogen bond forma-
tion between residues. To calculate the interatomic distances between statisti-
cally significantly correlated residues, a script was developed to measure the
distance between each pair of atoms within two different amino acids. The
interresidue distances are referred to as the shortest interatomic distance be-
tween any atoms in two residues. Residues within 8 Å in the protease structure
were considered near enough to interact (37).
Nucleotide sequence accession numbers. The majority of nucleotide sequences
from drug-naı¨ve patients have been submitted previously to GenBank (26). The
485 new sequences of isolates from patients treated with at least a PI within the
HAART regimens (3) were submitted to GenBank and assigned the following
accession numbers: AY855351 to AY855439, AY855441 to AY855458,
AY855460 to AY855502, AY855504 to AY855556, AY855558 to AY855773,
AY855775 to AY855795, AY855797 to AY855818, AY855820 to AY855836, and
AY995408 to AY995555.
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RESULTS
Novel protease mutations and their association with treat-
ment. By evaluating the entire protease sequences derived
from 457 drug-naı¨ve patients and 705 PI-treated patients, we
identified 17 novel protease mutations significantly associated
with treatment with PIs. These mutations were grouped in
three classes (Fig. 1).
Class I included mutations (K20I, K20T, A22V, E34Q,
E35G, K43T, K45R, K55R, T74S, I85V, Q92K, and C95F) that
occurred at a very low frequency (1%) in isolates from drug-
naı¨ve patients and showed a significant increase (P  0.05 to
0.001) in isolates from PI-treated patients. K20T, A22V, E34Q,
E35G, and T74S never occurred in isolates from drug-naı¨ve
patients, while K20T and T74S showed a remarkable increase
in frequency in isolates from PI-treated patients (up to 4.4%
and 7%, respectively; P  0.0001). The frequencies of the
K43T, K45R, I85V, Q92K, and C95F mutations never ex-
ceeded 4% in isolates from PI-treated patients, while the fre-
quencies of the K55R and K20I mutations reached 4.7% and
7.2%, respectively (P  0.001).
Class II included mutations (Q58E and I62V) that were
already occurring in isolates from drug-naı¨ve patients at a
frequency 1% but that showed a significant increase (P 
0.01) in isolates from PI-treated patients (Q58E from 1.5% to
5.2% and I62V from 24.5% to 35.9%).
Interestingly, and different from the other classes, class III
included mutations (T12A, L63Q, and H69N) that showed a
significant decrease in isolates from PI-treated patients com-
pared with that in isolates from drug-naı¨ve patients. In a com-
parison of drug-naı¨ve and PI-treated patients, the frequency of
T12A decreased from 6.3% to 2.8%, that of L63Q increased
from 4.2% to 1.6%, and that of H69N increased from 12.7% to
8.1% (P  0.05 for all comparisons).
Many class I mutations and both class II mutations showed
remarkable increases in frequency in isolates from patients
who had experienced more than three PIs (Table 1). In par-
ticular, for E34Q, Q58E, I62V, and C95F, the increase in
frequency observed in isolates from patients who experienced
more than three PIs was statistically significant (P  0.05)
compared with that observed not only in isolates from drug-
naı¨ve patients but also in isolates from patients who experi-
enced one or two PIs. On the other hand, class III mutations
showed a progressive decrease in prevalence, despite experi-
ence with increased numbers of PIs (Table 1).
Most class I mutations were significantly associated (P 
0.05) with the use of specific PIs (Table 1). In detail, K55R,
I85V, and C95F were specifically associated with indinavir
treatment; K20T, K45R, and T74S were specifically associated
with nelfinavir treatment; and E34Q and K43T were specifi-
cally associated with lopinavir/ritonavir treatment. K55R was
also associated with lopinavir/ritonavir and nelfinavir treat-
ment, while C95F was associated with saquinavir treatment.
None of the other mutations was significantly associated with
treatment with any specific PI, at least in this analysis.
Associations between protease mutations. A further step in
our study was to assess the association of novel protease mu-
tations with other mutations observed in PI-treated patients,
with the focus of our attention on those involved in PI resis-
tance.
Many mutations of class I or class II usually occurred in
isolates with one to four major PI resistance mutations. More
than three major mutations were found in 50% of the iso-
FIG. 1. Frequency of novel protease mutations in isolates from drug-naı¨ve and PI-treated HIV-1-infected patients. Statistically significant
differences were assessed by chi-square tests of independence. P values were significant at a false discovery rate of 0.05 following correction for
multiple comparisons. , P  0.05; , P  0.01; , P  0.001.
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lates from patients harboring one of the following mutations:
E34Q, K43T, K55R, I85V, Q92K, C95F, or Q58E (Fig. 2).
Among these, E34Q, K55R, and C95F were never found in the
absence of major mutations, whereas isolates with class III
mutations had a median number of major mutations ranging
from 0 to 1 (Fig. 2).
To identify the patterns of pairwise correlations between
novel mutations and specific protease mutations observed in
isolates from PI-treated patients, we calculated the pairwise
binomial correlation coefficient (phi) and its probability for
each pair of mutations (Table 2).
Class I and class II mutations were positively correlated as
pairs with many different PI resistance mutations. The most
frequently selected multidrug resistance mutation, L90M
(prevalence, 34.6%), was correlated with the novel mutation
K20I (phi  0.26), I62V (phi  0.20), or C95F (phi  0.17).
FIG. 2. Box plot representing the number of major HIV-1 drug resistance mutations (13; http://hivdb.Stanford.edu) associated with each novel
protease mutation. The medians, interquartile ranges, upper and lower whiskers, and outlier values (E) are shown.
TABLE 1. Association of novel protease mutations with PI treatment
Novel
mutation
Frequency (%) of mutations
Association with PIsaNaı¨ve
patients
(n  457)
PI-experienced patientsa
Two or fewer
(n  508)
Three or more
(n  193)
K20I 0.7 6.9 9.3
K20T 0 4.3 4.1 NFV (P  0.0001)
A22V 0 1.0 2.1
E34Q 0 0.4 3.6* LPV/r (P  0.0001)
E35G 0 1.6 1.6
K43T 0.2 2.6 6.2 LPV/r (P  0.002)
K45R 0.4 3.9 0.5 NFV (P  0.035)
K55R 0.7 3.7 7.3 IDV, LPV/r (P  0.0001); NFV (P  0.004)
T74S 0 6.3 8.8 NFV (P  0.003)
I85V 0.2 4.5 2.6 IDV (P  0.01)
Q92K 0.2 2.0 2.6
C95F 0.2 1.0 4.7* IDV (P  0.006); SQV (P  0.02)
Q58E 1.5 3.7 9.3*
I62V 24.5 33.1 43*
T12A 6.3 3.3 1.6
L63Q 4.2 1.8 1.0
H69N 12.7 9.1 5.7
a Values in boldface indicate statistically significant differences, corrected for multiple-hypothesis testing by the Benjamini-Hochberg method, with a false discovery
rate of 0.05 with respect to the results for isolates from drug-naı¨ve patients. Asterisks indicate statistically significant differences between isolates from patients
experienced with PIs less than or equal to two and isolates from patients experienced with three or more PIs.
b Statistically significant association (P  0.05) with PIs are reported. P values in boldface were significant at a false discovery rate of 0.05 following correction for
multiple-hypothesis testing. Abbreviations: NFV, nelfinavir; LPV/r, lopinavir/ritonavir; IDV, indinavir; SQV, saquinavir.
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I84V, another mutation conferring cross-resistance to all PIs,
had as novel covariates either I85V (phi  0.20) or Q92K (phi
 0.15). Different mutations at positions 82 and 54 were cor-
related as pairs with various novel mutations. V82A showed
pairwise correlations with either K43T (phi 0.26), K55R (phi
 0.21), or Q58E (phi  0.18), while V82T recognized either
C95F (phi  0.18) or I85V (phi  0.16) as a covariate. None
of the other variations at position 82 (F, L, and S) was signif-
icantly associated with any novel mutations, probably because
of their low frequency (1.1%). I54V, the most common
amino acid substitution at position 54 (15.6% of prevalence),
showed a very strong pairwise correlation with Q58E (phi 
0.27), but it was also correlated with K55R (phi 0.24). On the
other hand, mutation I54A, which occurred at a very low
frequency (1.7%), was correlated with K43T (phi  0.21).
The D30N and N88D mutations, specifically associated with
resistance to nelfinavir, were correlated only with K45R,
thus confirming the observed association of this mutation
with treatment with this drug. Mutation G48V, which con-
ferred high-level resistance to saquinavir (31), was associated
with either C95F (phi 0.27), K43T (phi 0.22), or T74S (phi
 0.21). Among these mutations, only C95F was associated
with saquinavir treatment.
Class III mutations did not show any positive correlations
with PI resistance-associated mutations; on the contrary, H69N
was negatively associated with the compensatory mutations
M36I (phi  0.14) and L10I (phi  0.13). In addition,
H69N showed a weak negative correlation with the major
mutation M46I (phi  0.05), although it was not statistically
significant.
TABLE 2. Significantly correlated pairs of mutations
Novel
mutation
Frequency
(no)a
Correlated
mutationb
Frequency
(no)a
Covariation
frequency
(%c)
Interresidue
distance
(Å)d
Phi
value P value
e
K20I 53 L90M 244 40 (75.5) 12.7 0.26 6.3e12
G73S 88 20 (37.7) 14.8 0.22 3.9e9
M46I 158 24 (45.3) 8.9 0.17 5.0e6
T74S 49 10 (18.9) 12.5 0.13 3.9e4
A71V 277 27 (51) 13.2 0.13 7.9e4
K20T 31 E35G 11 4 (13) 4.6 0.20 2.0e7
I15V 140 16 (51.6) 4.7 0.17 6.3e6
M36I 218 20 (64.5) 3.4 0.16 3.2e5
L90M 244 20 (64.5) 12.7 0.13 3.2e4
I13V 208 18 (58.1) 2.8 0.13 4.0e4
E34Q 9 L33F 26 4 (44.4) 1.3 0.25 6.3e11
F53L 23 3 (33.3) 8.4 0.19 3.2e7
E35G 11 K20T 31 4 (33.7) 4.6 0.20 2.0e7
M36I 218 11 (100) 1.3 0.19 5.0e7
K43T 25 V32I 34 10 (40) 11.1 0.31 6.3e17
I47V 14 6 (24) 9.4 0.30 1.0e15
V82A 145 19 (76) 16.8 0.26 3.2e12
G48V 40 8 (32) 13.1 0.22 6.3e9
I54A 12 4 (16) 9.5 0.21 2.0e8
M46I 158 13 (52) 7.0 0.14 3.2e4
L10I 245 17 (68) 24.1 0.13 4.0e4
I54V 110 10 (40) 9.5 0.13 6.3e4
K45R 20 N88D 66 8 (40) 9.5 0.18 2.0e6
D30N 98 8 (40) 4.5 0.13 6.3e4
K55R 33 M46I 158 24 (72.7) 3.5 0.27 1.3e12
I54V 110 18 (55.5) 1.3 0.24 2.5e10
L24I 37 9 (27.3) 19.6 0.22 6.33e9
V82A 145 19 (57.6) 11.7 0.21 2.5e8
L10I 245 24 (72.7) 19.7 0.19 3.2e7
R57K 73 10 (30.3) 4.7 0.15 1.3e4
T74S 49 G48V 40 11 (22.4) 13.1 0.21 5.0e8
I64V 137 24 (48.9) 7.0 0.20 6.3e8
K20I 53 10 (20) 13.9 0.13 4.0e4
V82A 145 19 (38.7) 12.7 0.12 1.0e3
I85V 28 Q92R 9 4 (14.3) 8.4 0.24 4.0e10
I84V 72 11 (39.2) 1.3 0.20 2.0e7
V82T 16 4 (14.3) 6.8 0.16 1.3e5
Continued on following page
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Cluster of correlated positions. The mathematical approach
used in our study let us define some clusters of mutated posi-
tions in which all possible pairs were mutually correlated.
Among the class I mutations, K20I, K43T, K45R, K55R, I85V,
and C95F were involved in one or more clusters that ranged in
size from three to seven mutated positions (Table 3). K45R
specifically clustered only with D30N and N88D. K43T was
involved in two clusters, both of which included V82A; one was
in the presence of I54V, while the other was in the presence of
both I47V and V32I. Similarly, C95F was involved in two
different and separated clusters. The most frequent cluster
(71.4% of isolates with C95F) included L90M with the com-
pensatory mutation I93L, while the other cluster (35.7% of
isolates with C95F) included V82A with other major mutations
(G48V and I54V). The presence of V82A was also observed in
a large cluster involving K55R together with the major muta-
tions M46I and I54V and the compensatory mutations L10I
and L24I. Clusters involving I85V contained only I84V as the
major mutation. K20I frequently clustered with the major mu-
tation I54V and the compensatory mutation M36I. The other
novel mutations of class I (A22V, K20T, E34Q, E35G, T74S,
and Q92K) were not found to cluster at a significant level with
PI resistance mutations.
Among the class II mutations, Q58E was involved in one
cluster (present in 32.4% of the isolates with Q58E) with three
major mutations (M46L, I54V, and V82A) and the compen-
satory mutation L10I. This cluster was the only one in which
M46L was predominant instead of M46I (which was present in
all other clusters involving mutations at this position). On the
other hand, I62V was involved in four types of clusters, with
prevalences ranging from 3.9% to 31.6%. Two of them in-
volved L90M with or without M46I. It is noteworthy that
among all clusters analyzed, the compensatory mutation L63P,
which was present at a very high frequency in isolates from
PI-treated patients (72%), was observed to be specifically in-
volved in only one cluster with I62V and L90M.
Locations of novel mutations in the three-dimensional
structure of protease. The distribution of the novel mutations
was widespread in the HIV-1 protease structure (Fig. 3A), and
the mutations were not directly involved in protease binding
sites and did not directly affect the dimerization interface (36).
However, several novel mutation residues were located at min-
TABLE 2—Continued
Novel
mutation
Frequency
(no)a
Correlated
mutationb
Frequency
(no)a
Covariation
frequency
(%c)
Interresidue
distance
(Å)d
Phi
value P value
e
I15V 140 14 (50) 7.7 0.15 5.0e5
L10I 245 19 (67.8) 8.2 0.15 6.3e5
M46I 158 13 (46.4) 15.5 0.12 1.0e3
I62V 253 17 (60.7) 9.9 0.11 2.5e3
Q92K 15 I84V 72 6 (40) 12.5 0.15 1.3e4
C95F 14 G48V 40 7 (50) 19.9 0.27 4.0e13
V82T 16 3 (21.4) 15.9 0.18 1.3e6
L90M 244 13 (92.8) 3.0 0.17 4.0e6
L10I 245 13 (92.8) 11.2 0.17 4.0e6
I54V 110 8 (57.1) 22.0 0.16 1.6e5
I93L 241 10 (71.4) 3.4 0.11 3.2e3
V82A 145 7 (50) 15.9 0.10 6.3e3*
Q58E 37 I54V 110 21 (56.7) 9.0 0.27 1.3e12
V82A 145 19 (51.3) 14.5 0.18 2.0e6
L10I 245 24 (64.8) 21.4 0.15 8.0e5
K20M 29 6 (16.2) 15.1 0.15 1.0e4
I62V 253 L90M 244 118 (46.6) 11.1 0.20 1.0e7
L10I 245 119 (47) 18.1 0.20 1.3e7
M36I 218 105 (41.5) 7.8 0.18 2.5e6
G73S 88 46 (18.2) 2.7 0.13 6.3e4
M46I 158 74 (29.2) 16.0 0.13 8.0e4
185V 28 17 (6.7) 9.9 0.11 2.5e3
I93L 241 99 (39.1) 10.4 0.10 1.0e2*
L63Q 11 I64V 137 8 (72.7) 1.3 0.17 6.3e6
H69N 57 I72V 83 15 (26.3) 7.2 0.14 3.2e4
M36I 218 5 (8.7) 15.1 0.14 1.6e4
L10I 245 7 (12.3) 13.1 0.13 4.0e4
a The frequency was determined for 705 isolates from PI-treated patients.
b Positive and negative correlations with phi  0.10 or phi  0.10, with P  0.05 are shown.
c The percentages were calculated for patients containing each specific novel mutation.
d The distance between wild-type residues is referred to as the shortest interatomic distance between any atoms in two residues.
e P values were corrected for multiple comparison (by the Benjamini-Hochberg method), with an false discovery rate of 0.05. Asterisks indicate P values not significant
at a false discovery rate of 0.05.
2020 SVICHER ET AL. ANTIMICROB. AGENTS CHEMOTHER.
imal interatomic distances from PI resistance-associated resi-
dues. In particular, residues 43, 45, and 55, which are located
in the flap, showed interatomic distances 8 Å with several PI
resistance-associated residues (residues 43 to 46, 45 to 30, 55 to
46, and 55 and 54), and residue 85 showed an interatomic
distance 8 Å with substrate binding sites (V82 and I84).
Overall, among the 61 statistically significant correlated pairs
of residues, 23 (37.7%) were within 8 Å of each other; and in
particular, 4 of the 23 correlated pairs of residues were con-
tiguous (residues 34 and 33, 35 and 36, 55 and 54, and 85 and
84) (Table 2).
Interestingly, the residue at position 45, which clustered with
residues 30 and 88, showed interatomic distances of 4.5 Å with
residue 30 and 9.5 Å with residue 88. Furthermore, the elec-
trostatic representation of the molecular surface of the pro-
tease with the mutations D30N, K45R, and N88D showed that
the D30N mutation determined a loss of a negative charge on
the protease surface that was restored by the mutation N88D,
while the mutation K45R, which resulted in an increase in the
size of the side chain, contributed to the enlargement of the
positively charged area near position 30 (Fig. 3B).
Finally, among the highly correlated residues, the novel res-
idue 95 showed interatomic distances 4 Å with residues 90
and 93. In particular, the three residues are involved in a
hydrogen bond network, and the carbonylic oxygen in the
backbone of residue 90 interacts with the nitrogens of residues
93, 94, and 95 (Fig. 3C).
DISCUSSION
Our study suggests that other HIV-1 protease mutations,
beyond the currently reported PI resistance-associated muta-
tions, may regulate the development or maintenance of resis-
tance to PIs. In fact, 17 novel mutations have been identified,
characterized, and grouped into three distinct classes. Class I
mutations were rare or completely absent in isolates from
drug-naı¨ve patients. In contrast, their frequency significantly
increased in isolates from patients treated with at least one PI,
thus suggesting the requirement of selective pressure with a PI
for their emergence at virological failure. In confirmation of
this, some mutations (K43T, T74S, I85V, Q92K, and C95F)
rapidly disappeared during therapy interruption, with the dy-
namics of disappearance being similar to that observed for
major PI resistance-associated mutations (data not shown).
The frequency of class II mutations, which were already
present in isolates from drug-naı¨ve patients, significantly in-
creased in isolates from PI-treated patients, thus suggesting the
positive association of these mutations with PI treatment. In
particular, I62V, observed in 24.5% of isolates from drug-naı¨ve
patients, may be considered a common protease polymor-
phism.
These results are consistent with recent analyses conducted
with a large number of protease sequences by two independent
groups. In fact, both class I and class II mutations were in-
cluded in a list of 22 newly described treatment-associated
mutated positions (37). The fact that Wu et al. (37) observed a
TABLE 3. Clusters involving novel mutations and PI resistance-associated mutations
Novel
mutationa PI resistance-associated mutation(s)
b Cluster
Cluster prevalence
No. (%) of
all PI-treated
patients
No./frequency no. of
novel mutation (%)
K20I M36I  I54V 20  36  54 12 (1.7) 12/53 (22.6)
L10I  I72L  G73S 10  20  72  73 7 (1) 7/53 (13.2)
L10I  I54V  A71V 10  20  54  71 6 (0.8) 6/53 (11.3)
L10I  M46I  A71V  G73S  184V  L90M 10  46  71  73  84  90 3 (0.4) 3/53 (5.6)
K43T I54V  V82A 43  54  82 12 (1.7) 12/25 (48)
V32I  147V  V82A 32  43  47  82 6 (0.8) 6/25 (24)
K45R D30N  N88D 30  45  88 6 (0.8) 6/21 (28.6)
K55R L10I  M46I  I93L 10  46  55  93 10 (1.4) 10/33 (30.3)
L10I  L24I  M46I  I54V  V82A 10  24  46  54  55  82 8 (1.1) 8/33 (24.2)
I85V L10I  I62V  I93L 10  62  85  93 11 (1.6) 11/28 (39.3)
L10I  I84V 10  84  85 11 (1.6) 11/28 (39.3)
I84V  Q92R 84  85  92 4 (0.6) 4/28 (14.3)
C95F L10I  L90M  I93L 10  90  93  95 10 (1.4) 10/14 (71.4)
L10I  G48V  I54V  V82A 10  48  54  82  95 5 (0.7) 5/14 (35.7)
Q58E L10I  M46L  I54V  V82A 10  46  54  58  82 12 (1.7) 12/37 (32.4)
I62V L10I  L63P  L90M 10  62  63  90 80 (11.3) 80/253 (31.6)
L10I  I72L/M/T/V  G73S 10  62  72  73 22 (3.1) 22/253 (8.7)
L10I  I85V  I93L 10  62  85  93 11 (1.6) 11/253 (4.3)
L10I  M46I  G73S  L90M  I93L 10  46  62  73  90  93 10 (1.4) 10/253 (3.9)
a Boldface indicates clusters that occurred at a frequency 1% in which a novel mutation occurred at a frequency of 20%.
b PI resistance-associated mutations occurring in the cluster with a frequency 50%.
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FIG. 3. Localization of novel mutations in the structure of HIV-1 protease. (A) A ribbon model of HIV-1 protease showing the three different
classes of novel mutations and all mutations correlated. (B) Insights into the protease molecular surface showing changes in charge distribution
due to mutations D30N, K45R, and N88D. Red and blue, negatively and positively charged regions, respectively. In panel 2 side chains of mutated
residues are rotated to minimize strong van der Waals clashes. (C) Hydrogen bond networks among residues at positions 90, 93, 94, and 95. Grey,
carbonium atoms; red, oxygen atoms; blue, nitrogen atoms; yellow, the sulfur atom of Cys.
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higher number of new treatment-associated mutated positions
may probably be related to the different number of patients
analyzed, the patients’ characteristics, and the therapeutic reg-
imens used. In addition, most class I and II mutations (K20T,
E34Q, K43T, K45R, K55R, T74S, I85V, Q92K, Q58E, and
I62V) were included as candidate mutations for drug resis-
tance or positive reproductive fitness by having a ratio of the
number of nonsynonymous mutations to the number of syn-
onymous mutations 1, with values similar to those observed
for the majority of the already-known PI resistance-associated
mutations (4).
Many class I and class II mutations were strongly correlated
(both in pairs and in clusters) with PI resistance-associated
mutations and rarely occurred in the absence of major muta-
tions, suggesting that they may require the accumulation of PI
resistance-associated mutations in the protease enzyme for
their emergence. In particular, correlations frequently involved
one or more multi-PI resistance-associated mutations at posi-
tions 82, 84, and 90, thus confirming the wide cross-resistance
that characterizes PIs. We have no evidence how each muta-
tion could influence (enhance) drug resistance or increase rep-
lication capacity; it is conceivable that class I and class II
mutations may act as minor mutations able to rescue the loss of
fitness or to increase the level of resistance. As confirmation of
these hypotheses, K20I and K20T were recently included in the
set of mutations associated with reduced susceptibility to
atazanavir and tipranavir, respectively, even if their exact role
has not been determined (13). Parkin et al. (24) included
E34Q, K43T, Q58E, and T74S in the list of lopinavir muta-
tional scores used as a predictor of reduced lopinavir suscep-
tibility; in particular, E34Q and K43T are associated with lopi-
navir resistance in the rules-based CREST algorithm (http:
//assign.dci.uwa.edu.au/crest/crest5_table.asp). Furthermore, it
was observed to be a better predictor of lopinavir resistance by
use of an artificial neural network when a set of mutations,
including K43T, K55R, Q58E, T74S, I85V, and C95F, was used
(34). Consistent with this report, our analysis shows that E34Q,
K43T, and K55R occurred in isolates from patients who failed
an antiretroviral therapy containing lopinavir/ritonavir and
correlated with mutations associated with lopinavir resistance
(13, 31). In fact, E34Q was specifically associated with either
L33F or F53L, and K43T was specifically associated with I54A
and clustered with multi-PI resistance mutations (V82A and
I54V or V82A, V32I, and I47V), while K55R clustered with
multi-PI resistance mutations (V82A, I54V, and M46I). There-
fore, these data strongly suggest that E34Q, K43T, and K55R
will need consideration in more than one resistance algorithm
to correctly predict lopinavir resistance. In addition, K55R
significantly occurred also in patients failing a nelfinavir-con-
taining regimen, thus supporting the previously reported asso-
ciation of K55R with reduced susceptibility to nelfinavir (18).
Similar to K55R, Q58E clustered with positions 10, 46, 54,
and 82; in this context, the most common amino acid substi-
tution at position 46 was M46L and not M46I. We then sup-
pose that M46I and M46L may have different compensatory
pathways mediated by K55R and Q58E, respectively, thus sup-
porting the hypothesis formulated by Hoffman et al. (12), who
suggested that as a consequence of different codon usage at
position 46, M46I and M46L lie along divergent evolutionary
pathways.
On the other hand, C95F clustered with G48V and V82A,
whose copresence reflects prolonged saquinavir exposure (30,
35). As C95F was associated with saquinavir use, we may sup-
pose that this mutation may contribute to saquinavir resis-
tance. However, C95F was also strongly associated with indi-
navir use and was strongly associated in a cluster with L90M
and I93L. Our structural analysis showed that residues at po-
sitions 90, 93, and 95 directly interact through a hydrogen bond
network that stabilizes the ending loop from positions 92 to 95
of the protease enzyme.
Two mutations (K45R and K20T) were specifically associ-
ated with nelfinavir. K45R occurred in isolates from patients
who failed a first-line regimen containing nelfinavir and
showed a highly specific association with nelfinavir-associated
mutations D30N and N88D (25, 28). Kaldor et al. (14) dem-
onstrated that the D30N mutation reduces a hydrogen bond
with bound nelfinavir. However, D30N also determines a loss
of a negative charge on the molecular surface of the protease
enzyme. The restoration of this negative charge is somewhat
related to the emergence of N88D, thus helping the overall
increase in protease efficiency. K45R, which results in an in-
creased size of the side chain, may contribute to an enlarge-
ment of the positively charged area around position 30. K20T
significantly occurred in patients who failed nelfinavir as the
second PI and was significantly correlated with the multi-PI
resistance-associated mutation L90M, suggesting that K20T
may contribute to L90M-mediated resistance to nelfinavir.
Also, K20I and I62V were strongly correlated with L90M, but
they were not associated with any specific PI, thus suggesting
that they may play their compensatory roles in the context of
cross-resistance.
Although biochemical experiments are required to demon-
strate the mechanism of correlation between pairs of residues,
our study provides preliminary hypotheses on the importance
of these novel mutations. In addition, the fact that many class
I and II residues are located at minimal interatomic distances
with their positively correlated PI resistance-associated resi-
dues in the three-dimensional protease structure confirms a
role of the local environment in the interactions among muta-
tions.
Class III mutations are common polymorphisms in isolates
from drug-naı¨ve patients, and their frequency decreased in
isolates from patients who failed an antiretroviral regimen
containing at least one PI, thus suggesting the negative asso-
ciation of these mutations with PI treatment and failure. Class
III mutations were rarely found in the presence of major mu-
tations and were never positively correlated with any PI resis-
tance-associated mutations. If anything, H69N showed nega-
tive correlations with the minor mutations M36I and L10I.
These data suggest a protective role for class III mutations that
may prevent the appearance of PI resistance-associated muta-
tions under PI pressure, thus contributing to increases in the
level of the genetic barrier to PI resistance. However, this
hypothesis needs confirmation in in vitro studies and clinical
practice.
It should be noted that all patients analyzed in this study
carried the HIV-1 clade B subtype. Further studies should also
investigate the prevalence and the role of the novel mutations
in non-B subtype clades. In fact, it is known that pathways of
viral evolution toward drug resistance may proceed through
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distinct steps and at different rates among different HIV-1
subtypes (33). Also, we cannot exclude the possibility that
novel mutations, and in particular, the observed patterns of
correlated mutations, may be the result of pharmacological
pressure imposed by the drug regimens that were used by our
cohort, while other treatment regimens may lead to the devel-
opment of pathways in part different from those that we ob-
served. Further studies and extended databases (with geno-
typic and/or phenotypic data) may provide insights regarding
this important point.
In conclusion, our study strongly suggests that PI resistance
is a very complex phenomenon and is regulated both positively
and negatively by a highly ordered network of mutations, which
also reflects the high genetic barrier to PI resistance. On this
basis, novel mutations must be taken into account to define
more precise algorithms able to correctly predict resistance to
antiretroviral drugs.
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